CRISPR Therapeutics AG's stock increased by 7.16% as it crossed above the 20-day SMA, reflecting positive momentum in the biotech sector.
This surge is attributed to Chardan maintaining a buy rating on CRISPR Therapeutics AG while lowering its price target to $74. The firm highlighted significant clinical progress with zugocaptagene geleucel, particularly noting a patient with systemic lupus erythematosus achieving drug-free clinical remission after treatment, showcasing the therapy's long-term efficacy. This positive clinical update is likely to bolster investor confidence in the company's future prospects.
The implications of these developments suggest a growing optimism around CRISPR's innovative therapies, especially in the context of the expanding gene therapy market, which is projected to reach $36.55 billion by 2032.
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
7 Hold
0 Sell
Moderate Buy
Current: 54.260
Low
40.00
Averages
68.88
High
105.00
Current: 54.260
Low
40.00
Averages
68.88
High
105.00
BofA
Alec Stranahan
Buy
downgrade
$90 -> $89
2026-01-22
Reason
BofA
Alec Stranahan
Price Target
$90 -> $89
AI Analysis
2026-01-22
downgrade
Buy
Reason
BofA analyst Alec Stranahan lowered the firm's price target on Crispr Therapeutics to $89 from $90 and keeps a Buy rating on the shares. The firm slightly reduced 2026 expectations for Casgevy, but still expects continued sequential growth in 2026, the analyst tells investors in an earnings preview for the group.
BofA
Alec Stranahan
Buy
downgrade
$93 -> $90
2026-01-06
Reason
BofA
Alec Stranahan
Price Target
$93 -> $90
2026-01-06
downgrade
Buy
Reason
BofA analyst Alec Stranahan lowered the firm's price target on Crispr Therapeutics to $90 from $93 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRSP
Unlock Now
Chardan
Buy
downgrade
$82 -> $74
2025-11-26
Reason
Chardan
Price Target
$82 -> $74
2025-11-26
downgrade
Buy
Reason
Chardan lowered the firm's price target on Crispr Therapeutics to $74 from $82 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report.
Citi
Yigal Nochomovitz
Buy
downgrade
$87 -> $77
2025-11-12
Reason
Citi
Yigal Nochomovitz
Price Target
$87 -> $77
2025-11-12
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Crispr Therapeutics to $77 from $87 and keeps a Buy rating on the shares.
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
